Electrophysiological effects of flecainide acetate on stretched guinea pig left atrial muscle fibers. 1993

D Inoue, and T Shirayama, and I Omori, and M Inoue, and R Sakai, and K Ishibashi, and H Miyazaki, and Y Yamahara, and T Tatsumi, and J Asayama
Second Department of Medicine, Kyoto Prefectural University of Medicine, Japan.

The electrophysiological effects of flecainide acetate (3 x 10(-6) M) on stretched atrial tissue were investigated using guinea-pig left atrial muscle fibers. Before stretching, the resting membrane potential was not affected by flecainide at 1 Hz, although the overshoot potential (Eov) and the action potential duration at 50% repolarization (APD50) were slightly but significantly decreased by 2 +/- 1 mV and 2 +/- 1 msec, respectively. The effective refractory period (ERP) was increased by 3 +/- 1 msec. The reduction of Vmax was 20.6 +/- 1.2%. The half-maximum potential (Vh) of the relationship between Vmax and the resting potential was shifted to become more negative by flecainide (from -60.6 +/- 2.1 mV to -63.2 +/- 1.7 mV). After 90-120 min of washout with drug-free Tyrode's solution, the tissue was mechanically stretched to 150% of its slack length. Stretching significantly decreased the Vmax by 16.9 +/- 3.1%, along with a slight but significant increase in ERP (3 +/- 1 msec) and shifted Vh to become more negative (from -60.6 +/- 2.1 to -63.1 +/- 1.8 mV). In the presence of flecainide, Vmax further decreased by 20.2 +/- 2.6%, and Vh shifted from -63.1 +/- 1.8 to -65.0 +/- 1.5 mV. Comparison with the control unstretched fibers showed that flecainide significantly decreased Vmax by 34.0 +/- 2.7%, reduced the resting membrane potential by 3 +/- 1 mV, decreased Eov by 4 +/- 1 mV, and shifted Vh from -60.6 +/- 2.1 to -65.0 +/- 1.5 mV, while the APD50 and ERP did not change. In conclusion, the reduction of Vmax in the presence of flecainide was much greater in the stretched atrial muscle fibers than in the unstretched fibers, because the Vmax-resting potential relationship was shifted towards more negative potentials by both flecainide and stretching. These results suggest that flecainide exerts a stronger antiarrhythmic action on stretched atrial muscle fibers than on normal fibers.

UI MeSH Term Description Entries
D008297 Male Males
D008564 Membrane Potentials The voltage differences across a membrane. For cellular membranes they are computed by subtracting the voltage measured outside the membrane from the voltage measured inside the membrane. They result from differences of inside versus outside concentration of potassium, sodium, chloride, and other ions across cells' or ORGANELLES membranes. For excitable cells, the resting membrane potentials range between -30 and -100 millivolts. Physical, chemical, or electrical stimuli can make a membrane potential more negative (hyperpolarization), or less negative (depolarization). Resting Potentials,Transmembrane Potentials,Delta Psi,Resting Membrane Potential,Transmembrane Electrical Potential Difference,Transmembrane Potential Difference,Difference, Transmembrane Potential,Differences, Transmembrane Potential,Membrane Potential,Membrane Potential, Resting,Membrane Potentials, Resting,Potential Difference, Transmembrane,Potential Differences, Transmembrane,Potential, Membrane,Potential, Resting,Potential, Transmembrane,Potentials, Membrane,Potentials, Resting,Potentials, Transmembrane,Resting Membrane Potentials,Resting Potential,Transmembrane Potential,Transmembrane Potential Differences
D004594 Electrophysiology The study of the generation and behavior of electrical charges in living organisms particularly the nervous system and the effects of electricity on living organisms.
D005260 Female Females
D005424 Flecainide A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS. Flecainide Acetate,Apocard,Flecadura,Flecainid-Isis,Flecainide Monoacetate,Flecainide Monoacetate, (+-)-Isomer,Flecainide Monoacetate, (R)-Isomer,Flecainide Monoacetate, (S)-Isomer,Flecainide, (R)-Isomer,Flecainide, (S)-Isomer,Flecainide, 5-HO-N-(6-oxo)-Derivative,Flecainide, 5-HO-N-(6-oxo)-Derivative, (+-)-Isomer,Flecatab,Flécaïne,R818,Tambocor,Flecainid Isis
D006168 Guinea Pigs A common name used for the genus Cavia. The most common species is Cavia porcellus which is the domesticated guinea pig used for pets and biomedical research. Cavia,Cavia porcellus,Guinea Pig,Pig, Guinea,Pigs, Guinea
D006321 Heart The hollow, muscular organ that maintains the circulation of the blood. Hearts
D006325 Heart Atria The chambers of the heart, to which the BLOOD returns from the circulation. Heart Atrium,Left Atrium,Right Atrium,Atria, Heart,Atrium, Heart,Atrium, Left,Atrium, Right
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

D Inoue, and T Shirayama, and I Omori, and M Inoue, and R Sakai, and K Ishibashi, and H Miyazaki, and Y Yamahara, and T Tatsumi, and J Asayama
November 1987, Journal of cardiovascular pharmacology,
D Inoue, and T Shirayama, and I Omori, and M Inoue, and R Sakai, and K Ishibashi, and H Miyazaki, and Y Yamahara, and T Tatsumi, and J Asayama
April 1995, Inflammation research : official journal of the European Histamine Research Society ... [et al.],
D Inoue, and T Shirayama, and I Omori, and M Inoue, and R Sakai, and K Ishibashi, and H Miyazaki, and Y Yamahara, and T Tatsumi, and J Asayama
May 1984, The Journal of pharmacology and experimental therapeutics,
D Inoue, and T Shirayama, and I Omori, and M Inoue, and R Sakai, and K Ishibashi, and H Miyazaki, and Y Yamahara, and T Tatsumi, and J Asayama
July 1987, Japanese heart journal,
D Inoue, and T Shirayama, and I Omori, and M Inoue, and R Sakai, and K Ishibashi, and H Miyazaki, and Y Yamahara, and T Tatsumi, and J Asayama
January 1989, General pharmacology,
D Inoue, and T Shirayama, and I Omori, and M Inoue, and R Sakai, and K Ishibashi, and H Miyazaki, and Y Yamahara, and T Tatsumi, and J Asayama
August 1980, Archives internationales de pharmacodynamie et de therapie,
D Inoue, and T Shirayama, and I Omori, and M Inoue, and R Sakai, and K Ishibashi, and H Miyazaki, and Y Yamahara, and T Tatsumi, and J Asayama
February 1985, European journal of pharmacology,
D Inoue, and T Shirayama, and I Omori, and M Inoue, and R Sakai, and K Ishibashi, and H Miyazaki, and Y Yamahara, and T Tatsumi, and J Asayama
March 1990, Cardiovascular research,
D Inoue, and T Shirayama, and I Omori, and M Inoue, and R Sakai, and K Ishibashi, and H Miyazaki, and Y Yamahara, and T Tatsumi, and J Asayama
October 1989, Journal of cardiovascular pharmacology,
D Inoue, and T Shirayama, and I Omori, and M Inoue, and R Sakai, and K Ishibashi, and H Miyazaki, and Y Yamahara, and T Tatsumi, and J Asayama
January 1970, The Journal of general physiology,
Copied contents to your clipboard!